Clinical trial

Adjuvant FEC Versus EP in Breast Cancer (MIG5)

NCT02450058

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date1996-11-01

PhasePHASE3

Study timeline

Study start (unknown)1996-11-01Date precision: month

Registry last updated2015-05-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Chemotherapy, Adjuvantunresolved

Interventions

5-fluorouracilDRUG

epirubicinDRUG · verified · RxNorm: epirubicin

cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

epirubicinDRUG · verified · RxNorm: epirubicin

paclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italylead sponsor

Mapped research locations

TorinoItaly2 PisaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02450058 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.